nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—CYP2E1—alcohol dependence	0.342	1	CbGaD
Thalidomide—CYP2E1—Disulfiram—alcohol dependence	0.0907	0.258	CbGbCtD
Thalidomide—CYP3A5—Disulfiram—alcohol dependence	0.0705	0.201	CbGbCtD
Thalidomide—CYP2E1—Citalopram—alcohol dependence	0.0646	0.184	CbGbCtD
Thalidomide—CYP2C9—Disulfiram—alcohol dependence	0.0473	0.135	CbGbCtD
Thalidomide—CYP2C19—Citalopram—alcohol dependence	0.0405	0.115	CbGbCtD
Thalidomide—CYP1A2—Citalopram—alcohol dependence	0.0374	0.107	CbGbCtD
Thalidomide—Menadione—MAOB—alcohol dependence	0.002	0.698	CrCbGaD
Thalidomide—TNF—blood—alcohol dependence	0.00189	0.0371	CbGeAlD
Thalidomide—NFKB1—forebrain—alcohol dependence	0.00161	0.0316	CbGeAlD
Thalidomide—NFKB1—cardiovascular system—alcohol dependence	0.00136	0.0267	CbGeAlD
Thalidomide—CRBN—forebrain—alcohol dependence	0.00135	0.0265	CbGeAlD
Thalidomide—FGFR2—brainstem—alcohol dependence	0.00125	0.0246	CbGeAlD
Thalidomide—CRBN—adrenal cortex—alcohol dependence	0.00125	0.0246	CbGeAlD
Thalidomide—NFKB1—gonad—alcohol dependence	0.00124	0.0243	CbGeAlD
Thalidomide—FGFR2—forebrain—alcohol dependence	0.00121	0.0238	CbGeAlD
Thalidomide—NFKB1—digestive system—alcohol dependence	0.00113	0.0222	CbGeAlD
Thalidomide—CRBN—pancreas—alcohol dependence	0.00111	0.0218	CbGeAlD
Thalidomide—NFKB1—blood—alcohol dependence	0.00108	0.0212	CbGeAlD
Thalidomide—CRBN—gonad—alcohol dependence	0.00104	0.0203	CbGeAlD
Thalidomide—FGFR2—cardiovascular system—alcohol dependence	0.00102	0.0201	CbGeAlD
Thalidomide—CRBN—digestive system—alcohol dependence	0.000949	0.0186	CbGeAlD
Thalidomide—NFKB1—endocrine gland—alcohol dependence	0.000935	0.0183	CbGeAlD
Thalidomide—CRBN—blood—alcohol dependence	0.000904	0.0177	CbGeAlD
Thalidomide—CRBN—midbrain—alcohol dependence	0.000892	0.0175	CbGeAlD
Thalidomide—NFKB1—testis—alcohol dependence	0.000892	0.0175	CbGeAlD
Thalidomide—NFKB1—nervous system—alcohol dependence	0.000875	0.0172	CbGeAlD
Thalidomide—Menadione—CYP2E1—alcohol dependence	0.000863	0.302	CrCbGaD
Thalidomide—FGFR2—digestive system—alcohol dependence	0.00085	0.0167	CbGeAlD
Thalidomide—NFKB1—liver—alcohol dependence	0.000843	0.0165	CbGeAlD
Thalidomide—NFKB1—central nervous system—alcohol dependence	0.000843	0.0165	CbGeAlD
Thalidomide—NFKB1—cerebellum—alcohol dependence	0.000824	0.0162	CbGeAlD
Thalidomide—FGFR2—blood—alcohol dependence	0.00081	0.0159	CbGeAlD
Thalidomide—CRBN—endocrine gland—alcohol dependence	0.000784	0.0154	CbGeAlD
Thalidomide—CRBN—testis—alcohol dependence	0.000748	0.0147	CbGeAlD
Thalidomide—CRBN—nervous system—alcohol dependence	0.000734	0.0144	CbGeAlD
Thalidomide—CRBN—liver—alcohol dependence	0.000707	0.0139	CbGeAlD
Thalidomide—CRBN—central nervous system—alcohol dependence	0.000706	0.0139	CbGeAlD
Thalidomide—FGFR2—endocrine gland—alcohol dependence	0.000702	0.0138	CbGeAlD
Thalidomide—CRBN—cerebellum—alcohol dependence	0.00069	0.0135	CbGeAlD
Thalidomide—FGFR2—testis—alcohol dependence	0.00067	0.0131	CbGeAlD
Thalidomide—NFKB1—brain—alcohol dependence	0.000669	0.0131	CbGeAlD
Thalidomide—FGFR2—nervous system—alcohol dependence	0.000657	0.0129	CbGeAlD
Thalidomide—FGFR2—liver—alcohol dependence	0.000633	0.0124	CbGeAlD
Thalidomide—FGFR2—central nervous system—alcohol dependence	0.000633	0.0124	CbGeAlD
Thalidomide—FGFR2—cerebellum—alcohol dependence	0.000619	0.0121	CbGeAlD
Thalidomide—CRBN—brain—alcohol dependence	0.000561	0.011	CbGeAlD
Thalidomide—FGFR2—brain—alcohol dependence	0.000502	0.00986	CbGeAlD
Thalidomide—PTGS1—forebrain—alcohol dependence	0.000385	0.00755	CbGeAlD
Thalidomide—CYP2C19—digestive system—alcohol dependence	0.000382	0.00749	CbGeAlD
Thalidomide—PTGS2—forebrain—alcohol dependence	0.000368	0.00722	CbGeAlD
Thalidomide—CYP2C19—blood—alcohol dependence	0.000364	0.00714	CbGeAlD
Thalidomide—CYP2C9—cardiovascular system—alcohol dependence	0.000357	0.007	CbGeAlD
Thalidomide—CYP3A5—pancreas—alcohol dependence	0.000352	0.00691	CbGeAlD
Thalidomide—PTGS2—adrenal cortex—alcohol dependence	0.000341	0.00669	CbGeAlD
Thalidomide—CYP2E1—cardiovascular system—alcohol dependence	0.000338	0.00663	CbGeAlD
Thalidomide—PTGS1—cardiovascular system—alcohol dependence	0.000326	0.00639	CbGeAlD
Thalidomide—CYP2C19—endocrine gland—alcohol dependence	0.000315	0.00619	CbGeAlD
Thalidomide—CYP1A2—digestive system—alcohol dependence	0.000312	0.00612	CbGeAlD
Thalidomide—PTGS2—cardiovascular system—alcohol dependence	0.000311	0.0061	CbGeAlD
Thalidomide—CYP1A1—digestive system—alcohol dependence	0.000308	0.00603	CbGeAlD
Thalidomide—PTGS2—pancreas—alcohol dependence	0.000302	0.00593	CbGeAlD
Thalidomide—CYP3A5—digestive system—alcohol dependence	0.000301	0.0059	CbGeAlD
Thalidomide—CYP1A2—blood—alcohol dependence	0.000297	0.00583	CbGeAlD
Thalidomide—CYP2C9—digestive system—alcohol dependence	0.000296	0.00581	CbGeAlD
Thalidomide—CYP1A1—blood—alcohol dependence	0.000293	0.00575	CbGeAlD
Thalidomide—CYP3A5—blood—alcohol dependence	0.000287	0.00562	CbGeAlD
Thalidomide—CYP2C19—liver—alcohol dependence	0.000284	0.00558	CbGeAlD
Thalidomide—CYP2C9—blood—alcohol dependence	0.000282	0.00553	CbGeAlD
Thalidomide—CYP2E1—digestive system—alcohol dependence	0.000281	0.0055	CbGeAlD
Thalidomide—PTGS1—digestive system—alcohol dependence	0.00027	0.0053	CbGeAlD
Thalidomide—CYP2E1—blood—alcohol dependence	0.000267	0.00524	CbGeAlD
Thalidomide—PTGS2—digestive system—alcohol dependence	0.000258	0.00507	CbGeAlD
Thalidomide—CYP1A2—endocrine gland—alcohol dependence	0.000258	0.00505	CbGeAlD
Thalidomide—PTGS1—blood—alcohol dependence	0.000257	0.00505	CbGeAlD
Thalidomide—CYP1A1—endocrine gland—alcohol dependence	0.000254	0.00499	CbGeAlD
Thalidomide—CYP3A5—endocrine gland—alcohol dependence	0.000249	0.00488	CbGeAlD
Thalidomide—PTGS2—blood—alcohol dependence	0.000246	0.00483	CbGeAlD
Thalidomide—CYP2C9—endocrine gland—alcohol dependence	0.000245	0.0048	CbGeAlD
Thalidomide—PTGS2—midbrain—alcohol dependence	0.000243	0.00477	CbGeAlD
Thalidomide—CYP1A1—nervous system—alcohol dependence	0.000238	0.00467	CbGeAlD
Thalidomide—CYP1A2—liver—alcohol dependence	0.000232	0.00456	CbGeAlD
Thalidomide—CYP2E1—endocrine gland—alcohol dependence	0.000232	0.00455	CbGeAlD
Thalidomide—CYP1A1—liver—alcohol dependence	0.000229	0.0045	CbGeAlD
Thalidomide—CYP1A1—central nervous system—alcohol dependence	0.000229	0.00449	CbGeAlD
Thalidomide—CYP3A5—liver—alcohol dependence	0.000224	0.0044	CbGeAlD
Thalidomide—PTGS1—endocrine gland—alcohol dependence	0.000223	0.00438	CbGeAlD
Thalidomide—CYP2E1—testis—alcohol dependence	0.000221	0.00434	CbGeAlD
Thalidomide—CYP2C9—liver—alcohol dependence	0.000221	0.00433	CbGeAlD
Thalidomide—CYP2E1—nervous system—alcohol dependence	0.000217	0.00426	CbGeAlD
Thalidomide—PTGS2—endocrine gland—alcohol dependence	0.000213	0.00419	CbGeAlD
Thalidomide—Muscle spasms—Acamprosate—alcohol dependence	0.000213	0.00124	CcSEcCtD
Thalidomide—Face oedema—Citalopram—alcohol dependence	0.000213	0.00124	CcSEcCtD
Thalidomide—Alopecia—Naltrexone—alcohol dependence	0.000213	0.00124	CcSEcCtD
Thalidomide—PTGS1—testis—alcohol dependence	0.000213	0.00418	CbGeAlD
Thalidomide—Mental disorder—Naltrexone—alcohol dependence	0.000211	0.00122	CcSEcCtD
Thalidomide—Cardiac arrest—Citalopram—alcohol dependence	0.00021	0.00122	CcSEcCtD
Thalidomide—Malnutrition—Naltrexone—alcohol dependence	0.00021	0.00122	CcSEcCtD
Thalidomide—Mood swings—Citalopram—alcohol dependence	0.000209	0.00121	CcSEcCtD
Thalidomide—PTGS1—nervous system—alcohol dependence	0.000209	0.0041	CbGeAlD
Thalidomide—CYP2E1—liver—alcohol dependence	0.000209	0.0041	CbGeAlD
Thalidomide—CYP2E1—central nervous system—alcohol dependence	0.000209	0.0041	CbGeAlD
Thalidomide—Tremor—Acamprosate—alcohol dependence	0.000208	0.0012	CcSEcCtD
Thalidomide—Ataxia—Citalopram—alcohol dependence	0.000208	0.0012	CcSEcCtD
Thalidomide—Flatulence—Naltrexone—alcohol dependence	0.000207	0.0012	CcSEcCtD
Thalidomide—Tension—Naltrexone—alcohol dependence	0.000206	0.00119	CcSEcCtD
Thalidomide—Ill-defined disorder—Acamprosate—alcohol dependence	0.000206	0.00119	CcSEcCtD
Thalidomide—Dysgeusia—Naltrexone—alcohol dependence	0.000206	0.00119	CcSEcCtD
Thalidomide—Dehydration—Citalopram—alcohol dependence	0.000205	0.00119	CcSEcCtD
Thalidomide—Anaemia—Acamprosate—alcohol dependence	0.000205	0.00119	CcSEcCtD
Thalidomide—CYP2E1—cerebellum—alcohol dependence	0.000204	0.00401	CbGeAlD
Thalidomide—Liver function test abnormal—Citalopram—alcohol dependence	0.000204	0.00118	CcSEcCtD
Thalidomide—Agitation—Acamprosate—alcohol dependence	0.000204	0.00118	CcSEcCtD
Thalidomide—Nervousness—Naltrexone—alcohol dependence	0.000204	0.00118	CcSEcCtD
Thalidomide—Back pain—Naltrexone—alcohol dependence	0.000203	0.00118	CcSEcCtD
Thalidomide—Angioedema—Acamprosate—alcohol dependence	0.000203	0.00118	CcSEcCtD
Thalidomide—Dry skin—Citalopram—alcohol dependence	0.000202	0.00117	CcSEcCtD
Thalidomide—Muscle spasms—Naltrexone—alcohol dependence	0.000202	0.00117	CcSEcCtD
Thalidomide—Orthostatic hypotension—Citalopram—alcohol dependence	0.000202	0.00117	CcSEcCtD
Thalidomide—PTGS1—central nervous system—alcohol dependence	0.000201	0.00395	CbGeAlD
Thalidomide—Hypokalaemia—Citalopram—alcohol dependence	0.000201	0.00117	CcSEcCtD
Thalidomide—Malaise—Acamprosate—alcohol dependence	0.0002	0.00116	CcSEcCtD
Thalidomide—PTGS2—nervous system—alcohol dependence	0.0002	0.00392	CbGeAlD
Thalidomide—Breast disorder—Citalopram—alcohol dependence	0.0002	0.00116	CcSEcCtD
Thalidomide—Vertigo—Acamprosate—alcohol dependence	0.000199	0.00116	CcSEcCtD
Thalidomide—Syncope—Acamprosate—alcohol dependence	0.000199	0.00115	CcSEcCtD
Thalidomide—Cramp muscle—Citalopram—alcohol dependence	0.000199	0.00115	CcSEcCtD
Thalidomide—Toxic epidermal necrolysis—Citalopram—alcohol dependence	0.000199	0.00115	CcSEcCtD
Thalidomide—Aspartate aminotransferase increased—Citalopram—alcohol dependence	0.000199	0.00115	CcSEcCtD
Thalidomide—Leukopenia—Acamprosate—alcohol dependence	0.000199	0.00115	CcSEcCtD
Thalidomide—Vision blurred—Naltrexone—alcohol dependence	0.000198	0.00115	CcSEcCtD
Thalidomide—Tremor—Naltrexone—alcohol dependence	0.000197	0.00114	CcSEcCtD
Thalidomide—Palpitations—Acamprosate—alcohol dependence	0.000196	0.00114	CcSEcCtD
Thalidomide—Loss of consciousness—Acamprosate—alcohol dependence	0.000195	0.00113	CcSEcCtD
Thalidomide—Muscular weakness—Citalopram—alcohol dependence	0.000195	0.00113	CcSEcCtD
Thalidomide—Alanine aminotransferase increased—Citalopram—alcohol dependence	0.000195	0.00113	CcSEcCtD
Thalidomide—Ill-defined disorder—Naltrexone—alcohol dependence	0.000195	0.00113	CcSEcCtD
Thalidomide—Cough—Acamprosate—alcohol dependence	0.000194	0.00112	CcSEcCtD
Thalidomide—Agitation—Naltrexone—alcohol dependence	0.000193	0.00112	CcSEcCtD
Thalidomide—PTGS2—liver—alcohol dependence	0.000192	0.00378	CbGeAlD
Thalidomide—PTGS2—central nervous system—alcohol dependence	0.000192	0.00377	CbGeAlD
Thalidomide—Convulsion—Acamprosate—alcohol dependence	0.000192	0.00111	CcSEcCtD
Thalidomide—Abdominal distension—Citalopram—alcohol dependence	0.000192	0.00111	CcSEcCtD
Thalidomide—Angioedema—Naltrexone—alcohol dependence	0.000192	0.00111	CcSEcCtD
Thalidomide—Hypertension—Acamprosate—alcohol dependence	0.000192	0.00111	CcSEcCtD
Thalidomide—Dysphagia—Citalopram—alcohol dependence	0.000191	0.00111	CcSEcCtD
Thalidomide—Influenza—Citalopram—alcohol dependence	0.000191	0.00111	CcSEcCtD
Thalidomide—Malaise—Naltrexone—alcohol dependence	0.000189	0.0011	CcSEcCtD
Thalidomide—Eosinophilia—Citalopram—alcohol dependence	0.000189	0.0011	CcSEcCtD
Thalidomide—Arthralgia—Acamprosate—alcohol dependence	0.000189	0.00109	CcSEcCtD
Thalidomide—Chest pain—Acamprosate—alcohol dependence	0.000189	0.00109	CcSEcCtD
Thalidomide—Myalgia—Acamprosate—alcohol dependence	0.000189	0.00109	CcSEcCtD
Thalidomide—Syncope—Naltrexone—alcohol dependence	0.000188	0.00109	CcSEcCtD
Thalidomide—Anxiety—Acamprosate—alcohol dependence	0.000188	0.00109	CcSEcCtD
Thalidomide—PTGS2—cerebellum—alcohol dependence	0.000188	0.00369	CbGeAlD
Thalidomide—Bronchospasm—Citalopram—alcohol dependence	0.000188	0.00109	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Acamprosate—alcohol dependence	0.000188	0.00109	CcSEcCtD
Thalidomide—Pancreatitis—Citalopram—alcohol dependence	0.000187	0.00108	CcSEcCtD
Thalidomide—Discomfort—Acamprosate—alcohol dependence	0.000187	0.00108	CcSEcCtD
Thalidomide—Angina pectoris—Citalopram—alcohol dependence	0.000186	0.00108	CcSEcCtD
Thalidomide—Palpitations—Naltrexone—alcohol dependence	0.000185	0.00108	CcSEcCtD
Thalidomide—Dry mouth—Acamprosate—alcohol dependence	0.000185	0.00107	CcSEcCtD
Thalidomide—Loss of consciousness—Naltrexone—alcohol dependence	0.000184	0.00107	CcSEcCtD
Thalidomide—Bronchitis—Citalopram—alcohol dependence	0.000184	0.00106	CcSEcCtD
Thalidomide—Cough—Naltrexone—alcohol dependence	0.000183	0.00106	CcSEcCtD
Thalidomide—Confusional state—Acamprosate—alcohol dependence	0.000183	0.00106	CcSEcCtD
Thalidomide—Convulsion—Naltrexone—alcohol dependence	0.000182	0.00105	CcSEcCtD
Thalidomide—CYP1A1—brain—alcohol dependence	0.000182	0.00357	CbGeAlD
Thalidomide—Pancytopenia—Citalopram—alcohol dependence	0.000181	0.00105	CcSEcCtD
Thalidomide—Hypertension—Naltrexone—alcohol dependence	0.000181	0.00105	CcSEcCtD
Thalidomide—Infection—Acamprosate—alcohol dependence	0.00018	0.00104	CcSEcCtD
Thalidomide—Myalgia—Naltrexone—alcohol dependence	0.000179	0.00104	CcSEcCtD
Thalidomide—Arthralgia—Naltrexone—alcohol dependence	0.000179	0.00104	CcSEcCtD
Thalidomide—Chest pain—Naltrexone—alcohol dependence	0.000179	0.00104	CcSEcCtD
Thalidomide—Shock—Acamprosate—alcohol dependence	0.000178	0.00103	CcSEcCtD
Thalidomide—Anxiety—Naltrexone—alcohol dependence	0.000178	0.00103	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Naltrexone—alcohol dependence	0.000177	0.00103	CcSEcCtD
Thalidomide—Upper respiratory tract infection—Citalopram—alcohol dependence	0.000177	0.00103	CcSEcCtD
Thalidomide—Thrombocytopenia—Acamprosate—alcohol dependence	0.000177	0.00103	CcSEcCtD
Thalidomide—Tachycardia—Acamprosate—alcohol dependence	0.000177	0.00102	CcSEcCtD
Thalidomide—Discomfort—Naltrexone—alcohol dependence	0.000177	0.00102	CcSEcCtD
Thalidomide—Pollakiuria—Citalopram—alcohol dependence	0.000176	0.00102	CcSEcCtD
Thalidomide—Skin disorder—Acamprosate—alcohol dependence	0.000176	0.00102	CcSEcCtD
Thalidomide—Erectile dysfunction—Citalopram—alcohol dependence	0.000176	0.00102	CcSEcCtD
Thalidomide—Hyperhidrosis—Acamprosate—alcohol dependence	0.000175	0.00101	CcSEcCtD
Thalidomide—Dry mouth—Naltrexone—alcohol dependence	0.000175	0.00101	CcSEcCtD
Thalidomide—Photosensitivity reaction—Citalopram—alcohol dependence	0.000174	0.00101	CcSEcCtD
Thalidomide—Weight increased—Citalopram—alcohol dependence	0.000174	0.00101	CcSEcCtD
Thalidomide—Confusional state—Naltrexone—alcohol dependence	0.000173	0.001	CcSEcCtD
Thalidomide—Weight decreased—Citalopram—alcohol dependence	0.000173	0.001	CcSEcCtD
Thalidomide—Anorexia—Acamprosate—alcohol dependence	0.000173	0.001	CcSEcCtD
Thalidomide—Hyperglycaemia—Citalopram—alcohol dependence	0.000172	0.000998	CcSEcCtD
Thalidomide—Oedema—Naltrexone—alcohol dependence	0.000171	0.000993	CcSEcCtD
Thalidomide—Pneumonia—Citalopram—alcohol dependence	0.000171	0.000992	CcSEcCtD
Thalidomide—Infection—Naltrexone—alcohol dependence	0.00017	0.000986	CcSEcCtD
Thalidomide—Infestation NOS—Citalopram—alcohol dependence	0.00017	0.000986	CcSEcCtD
Thalidomide—Infestation—Citalopram—alcohol dependence	0.00017	0.000986	CcSEcCtD
Thalidomide—Depression—Citalopram—alcohol dependence	0.00017	0.000984	CcSEcCtD
Thalidomide—Hypotension—Acamprosate—alcohol dependence	0.000169	0.000981	CcSEcCtD
Thalidomide—Stevens-Johnson syndrome—Citalopram—alcohol dependence	0.000169	0.000978	CcSEcCtD
Thalidomide—Shock—Naltrexone—alcohol dependence	0.000169	0.000977	CcSEcCtD
Thalidomide—Nervous system disorder—Naltrexone—alcohol dependence	0.000168	0.000974	CcSEcCtD
Thalidomide—Acute coronary syndrome—Citalopram—alcohol dependence	0.000168	0.000972	CcSEcCtD
Thalidomide—Tachycardia—Naltrexone—alcohol dependence	0.000167	0.000969	CcSEcCtD
Thalidomide—Neuropathy peripheral—Citalopram—alcohol dependence	0.000167	0.000967	CcSEcCtD
Thalidomide—Myocardial infarction—Citalopram—alcohol dependence	0.000167	0.000967	CcSEcCtD
Thalidomide—Skin disorder—Naltrexone—alcohol dependence	0.000166	0.000965	CcSEcCtD
Thalidomide—Stomatitis—Citalopram—alcohol dependence	0.000166	0.000962	CcSEcCtD
Thalidomide—CYP2E1—brain—alcohol dependence	0.000166	0.00325	CbGeAlD
Thalidomide—Hyperhidrosis—Naltrexone—alcohol dependence	0.000166	0.00096	CcSEcCtD
Thalidomide—Conjunctivitis—Citalopram—alcohol dependence	0.000165	0.000959	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Acamprosate—alcohol dependence	0.000165	0.000956	CcSEcCtD
Thalidomide—Insomnia—Acamprosate—alcohol dependence	0.000164	0.000949	CcSEcCtD
Thalidomide—Anorexia—Naltrexone—alcohol dependence	0.000163	0.000947	CcSEcCtD
Thalidomide—Sweating—Citalopram—alcohol dependence	0.000163	0.000946	CcSEcCtD
Thalidomide—Paraesthesia—Acamprosate—alcohol dependence	0.000163	0.000942	CcSEcCtD
Thalidomide—Haematuria—Citalopram—alcohol dependence	0.000162	0.000941	CcSEcCtD
Thalidomide—Dyspnoea—Acamprosate—alcohol dependence	0.000161	0.000936	CcSEcCtD
Thalidomide—Somnolence—Acamprosate—alcohol dependence	0.000161	0.000933	CcSEcCtD
Thalidomide—Epistaxis—Citalopram—alcohol dependence	0.000161	0.00093	CcSEcCtD
Thalidomide—PTGS1—brain—alcohol dependence	0.00016	0.00313	CbGeAlD
Thalidomide—Sinusitis—Citalopram—alcohol dependence	0.00016	0.000926	CcSEcCtD
Thalidomide—Dyspepsia—Acamprosate—alcohol dependence	0.000159	0.000924	CcSEcCtD
Thalidomide—Agranulocytosis—Citalopram—alcohol dependence	0.000159	0.000921	CcSEcCtD
Thalidomide—Decreased appetite—Acamprosate—alcohol dependence	0.000157	0.000912	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Acamprosate—alcohol dependence	0.000156	0.000906	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Naltrexone—alcohol dependence	0.000156	0.000905	CcSEcCtD
Thalidomide—Bradycardia—Citalopram—alcohol dependence	0.000156	0.000902	CcSEcCtD
Thalidomide—Insomnia—Naltrexone—alcohol dependence	0.000155	0.000898	CcSEcCtD
Thalidomide—Pain—Acamprosate—alcohol dependence	0.000155	0.000897	CcSEcCtD
Thalidomide—Constipation—Acamprosate—alcohol dependence	0.000155	0.000897	CcSEcCtD
Thalidomide—Paraesthesia—Naltrexone—alcohol dependence	0.000154	0.000892	CcSEcCtD
Thalidomide—Rhinitis—Citalopram—alcohol dependence	0.000153	0.000888	CcSEcCtD
Thalidomide—Hepatitis—Citalopram—alcohol dependence	0.000153	0.000886	CcSEcCtD
Thalidomide—Dyspnoea—Naltrexone—alcohol dependence	0.000153	0.000885	CcSEcCtD
Thalidomide—PTGS2—brain—alcohol dependence	0.000153	0.003	CbGeAlD
Thalidomide—Somnolence—Naltrexone—alcohol dependence	0.000152	0.000883	CcSEcCtD
Thalidomide—Hypoaesthesia—Citalopram—alcohol dependence	0.000152	0.000881	CcSEcCtD
Thalidomide—Pharyngitis—Citalopram—alcohol dependence	0.000152	0.000879	CcSEcCtD
Thalidomide—Urinary tract disorder—Citalopram—alcohol dependence	0.000151	0.000875	CcSEcCtD
Thalidomide—Oedema peripheral—Citalopram—alcohol dependence	0.000151	0.000872	CcSEcCtD
Thalidomide—Urethral disorder—Citalopram—alcohol dependence	0.00015	0.000868	CcSEcCtD
Thalidomide—Feeling abnormal—Acamprosate—alcohol dependence	0.000149	0.000865	CcSEcCtD
Thalidomide—Decreased appetite—Naltrexone—alcohol dependence	0.000149	0.000863	CcSEcCtD
Thalidomide—Gastrointestinal pain—Acamprosate—alcohol dependence	0.000148	0.000858	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Naltrexone—alcohol dependence	0.000148	0.000857	CcSEcCtD
Thalidomide—Fatigue—Naltrexone—alcohol dependence	0.000148	0.000856	CcSEcCtD
Thalidomide—Visual impairment—Citalopram—alcohol dependence	0.000147	0.000853	CcSEcCtD
Thalidomide—Pain—Naltrexone—alcohol dependence	0.000146	0.000849	CcSEcCtD
Thalidomide—Constipation—Naltrexone—alcohol dependence	0.000146	0.000849	CcSEcCtD
Thalidomide—Erythema multiforme—Citalopram—alcohol dependence	0.000144	0.000837	CcSEcCtD
Thalidomide—Urticaria—Acamprosate—alcohol dependence	0.000144	0.000834	CcSEcCtD
Thalidomide—Abdominal pain—Acamprosate—alcohol dependence	0.000143	0.00083	CcSEcCtD
Thalidomide—Body temperature increased—Acamprosate—alcohol dependence	0.000143	0.00083	CcSEcCtD
Thalidomide—Eye disorder—Citalopram—alcohol dependence	0.000143	0.000828	CcSEcCtD
Thalidomide—Tinnitus—Citalopram—alcohol dependence	0.000142	0.000826	CcSEcCtD
Thalidomide—Cardiac disorder—Citalopram—alcohol dependence	0.000142	0.000822	CcSEcCtD
Thalidomide—Feeling abnormal—Naltrexone—alcohol dependence	0.000141	0.000818	CcSEcCtD
Thalidomide—Gastrointestinal pain—Naltrexone—alcohol dependence	0.00014	0.000812	CcSEcCtD
Thalidomide—Angiopathy—Citalopram—alcohol dependence	0.000139	0.000803	CcSEcCtD
Thalidomide—Immune system disorder—Citalopram—alcohol dependence	0.000138	0.0008	CcSEcCtD
Thalidomide—Mediastinal disorder—Citalopram—alcohol dependence	0.000138	0.000798	CcSEcCtD
Thalidomide—Chills—Citalopram—alcohol dependence	0.000137	0.000795	CcSEcCtD
Thalidomide—Arrhythmia—Citalopram—alcohol dependence	0.000136	0.000791	CcSEcCtD
Thalidomide—Urticaria—Naltrexone—alcohol dependence	0.000136	0.000789	CcSEcCtD
Thalidomide—Abdominal pain—Naltrexone—alcohol dependence	0.000135	0.000785	CcSEcCtD
Thalidomide—Body temperature increased—Naltrexone—alcohol dependence	0.000135	0.000785	CcSEcCtD
Thalidomide—Alopecia—Citalopram—alcohol dependence	0.000135	0.000783	CcSEcCtD
Thalidomide—Mental disorder—Citalopram—alcohol dependence	0.000134	0.000776	CcSEcCtD
Thalidomide—Hypersensitivity—Acamprosate—alcohol dependence	0.000133	0.000773	CcSEcCtD
Thalidomide—Malnutrition—Citalopram—alcohol dependence	0.000133	0.000771	CcSEcCtD
Thalidomide—Flatulence—Citalopram—alcohol dependence	0.000131	0.00076	CcSEcCtD
Thalidomide—Tension—Citalopram—alcohol dependence	0.000131	0.000756	CcSEcCtD
Thalidomide—Dysgeusia—Citalopram—alcohol dependence	0.00013	0.000755	CcSEcCtD
Thalidomide—Asthenia—Acamprosate—alcohol dependence	0.00013	0.000753	CcSEcCtD
Thalidomide—Nervousness—Citalopram—alcohol dependence	0.000129	0.000749	CcSEcCtD
Thalidomide—Back pain—Citalopram—alcohol dependence	0.000129	0.000746	CcSEcCtD
Thalidomide—Pruritus—Acamprosate—alcohol dependence	0.000128	0.000743	CcSEcCtD
Thalidomide—Muscle spasms—Citalopram—alcohol dependence	0.000128	0.000741	CcSEcCtD
Thalidomide—Hypersensitivity—Naltrexone—alcohol dependence	0.000126	0.000732	CcSEcCtD
Thalidomide—Vision blurred—Citalopram—alcohol dependence	0.000125	0.000727	CcSEcCtD
Thalidomide—Tremor—Citalopram—alcohol dependence	0.000125	0.000722	CcSEcCtD
Thalidomide—Diarrhoea—Acamprosate—alcohol dependence	0.000124	0.000718	CcSEcCtD
Thalidomide—Ill-defined disorder—Citalopram—alcohol dependence	0.000123	0.000715	CcSEcCtD
Thalidomide—Anaemia—Citalopram—alcohol dependence	0.000123	0.000713	CcSEcCtD
Thalidomide—Asthenia—Naltrexone—alcohol dependence	0.000123	0.000712	CcSEcCtD
Thalidomide—Agitation—Citalopram—alcohol dependence	0.000122	0.000708	CcSEcCtD
Thalidomide—Angioedema—Citalopram—alcohol dependence	0.000122	0.000704	CcSEcCtD
Thalidomide—Pruritus—Naltrexone—alcohol dependence	0.000121	0.000703	CcSEcCtD
Thalidomide—Malaise—Citalopram—alcohol dependence	0.00012	0.000695	CcSEcCtD
Thalidomide—Dizziness—Acamprosate—alcohol dependence	0.00012	0.000694	CcSEcCtD
Thalidomide—Vertigo—Citalopram—alcohol dependence	0.000119	0.000693	CcSEcCtD
Thalidomide—Syncope—Citalopram—alcohol dependence	0.000119	0.000691	CcSEcCtD
Thalidomide—Leukopenia—Citalopram—alcohol dependence	0.000119	0.00069	CcSEcCtD
Thalidomide—Palpitations—Citalopram—alcohol dependence	0.000118	0.000681	CcSEcCtD
Thalidomide—Diarrhoea—Naltrexone—alcohol dependence	0.000117	0.000679	CcSEcCtD
Thalidomide—Loss of consciousness—Citalopram—alcohol dependence	0.000117	0.000678	CcSEcCtD
Thalidomide—Cough—Citalopram—alcohol dependence	0.000116	0.000673	CcSEcCtD
Thalidomide—Convulsion—Citalopram—alcohol dependence	0.000115	0.000668	CcSEcCtD
Thalidomide—Vomiting—Acamprosate—alcohol dependence	0.000115	0.000667	CcSEcCtD
Thalidomide—Hypertension—Citalopram—alcohol dependence	0.000115	0.000666	CcSEcCtD
Thalidomide—Rash—Acamprosate—alcohol dependence	0.000114	0.000662	CcSEcCtD
Thalidomide—Dermatitis—Acamprosate—alcohol dependence	0.000114	0.000661	CcSEcCtD
Thalidomide—Headache—Acamprosate—alcohol dependence	0.000113	0.000657	CcSEcCtD
Thalidomide—Dizziness—Naltrexone—alcohol dependence	0.000113	0.000657	CcSEcCtD
Thalidomide—Myalgia—Citalopram—alcohol dependence	0.000113	0.000656	CcSEcCtD
Thalidomide—Arthralgia—Citalopram—alcohol dependence	0.000113	0.000656	CcSEcCtD
Thalidomide—Chest pain—Citalopram—alcohol dependence	0.000113	0.000656	CcSEcCtD
Thalidomide—Anxiety—Citalopram—alcohol dependence	0.000113	0.000654	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Citalopram—alcohol dependence	0.000112	0.000652	CcSEcCtD
Thalidomide—Discomfort—Citalopram—alcohol dependence	0.000112	0.000648	CcSEcCtD
Thalidomide—Dry mouth—Citalopram—alcohol dependence	0.000111	0.000642	CcSEcCtD
Thalidomide—Confusional state—Citalopram—alcohol dependence	0.000109	0.000634	CcSEcCtD
Thalidomide—Vomiting—Naltrexone—alcohol dependence	0.000109	0.000631	CcSEcCtD
Thalidomide—Oedema—Citalopram—alcohol dependence	0.000109	0.000629	CcSEcCtD
Thalidomide—Rash—Naltrexone—alcohol dependence	0.000108	0.000626	CcSEcCtD
Thalidomide—Dermatitis—Naltrexone—alcohol dependence	0.000108	0.000626	CcSEcCtD
Thalidomide—Infection—Citalopram—alcohol dependence	0.000108	0.000625	CcSEcCtD
Thalidomide—Nausea—Acamprosate—alcohol dependence	0.000108	0.000623	CcSEcCtD
Thalidomide—Headache—Naltrexone—alcohol dependence	0.000107	0.000622	CcSEcCtD
Thalidomide—Shock—Citalopram—alcohol dependence	0.000107	0.000619	CcSEcCtD
Thalidomide—Nervous system disorder—Citalopram—alcohol dependence	0.000106	0.000617	CcSEcCtD
Thalidomide—Thrombocytopenia—Citalopram—alcohol dependence	0.000106	0.000616	CcSEcCtD
Thalidomide—Tachycardia—Citalopram—alcohol dependence	0.000106	0.000614	CcSEcCtD
Thalidomide—Skin disorder—Citalopram—alcohol dependence	0.000105	0.000611	CcSEcCtD
Thalidomide—Hyperhidrosis—Citalopram—alcohol dependence	0.000105	0.000608	CcSEcCtD
Thalidomide—Anorexia—Citalopram—alcohol dependence	0.000103	0.0006	CcSEcCtD
Thalidomide—Nausea—Naltrexone—alcohol dependence	0.000102	0.00059	CcSEcCtD
Thalidomide—Hypotension—Citalopram—alcohol dependence	0.000101	0.000588	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Citalopram—alcohol dependence	9.89e-05	0.000573	CcSEcCtD
Thalidomide—Insomnia—Citalopram—alcohol dependence	9.82e-05	0.000569	CcSEcCtD
Thalidomide—Paraesthesia—Citalopram—alcohol dependence	9.75e-05	0.000565	CcSEcCtD
Thalidomide—Dyspnoea—Citalopram—alcohol dependence	9.68e-05	0.000561	CcSEcCtD
Thalidomide—Somnolence—Citalopram—alcohol dependence	9.65e-05	0.000559	CcSEcCtD
Thalidomide—Dyspepsia—Citalopram—alcohol dependence	9.55e-05	0.000554	CcSEcCtD
Thalidomide—Decreased appetite—Citalopram—alcohol dependence	9.44e-05	0.000547	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Citalopram—alcohol dependence	9.37e-05	0.000543	CcSEcCtD
Thalidomide—Fatigue—Citalopram—alcohol dependence	9.36e-05	0.000542	CcSEcCtD
Thalidomide—Pain—Citalopram—alcohol dependence	9.28e-05	0.000538	CcSEcCtD
Thalidomide—Constipation—Citalopram—alcohol dependence	9.28e-05	0.000538	CcSEcCtD
Thalidomide—Feeling abnormal—Citalopram—alcohol dependence	8.94e-05	0.000518	CcSEcCtD
Thalidomide—Gastrointestinal pain—Citalopram—alcohol dependence	8.88e-05	0.000514	CcSEcCtD
Thalidomide—Urticaria—Citalopram—alcohol dependence	8.62e-05	0.0005	CcSEcCtD
Thalidomide—Abdominal pain—Citalopram—alcohol dependence	8.58e-05	0.000497	CcSEcCtD
Thalidomide—Body temperature increased—Citalopram—alcohol dependence	8.58e-05	0.000497	CcSEcCtD
Thalidomide—Hypersensitivity—Citalopram—alcohol dependence	8e-05	0.000464	CcSEcCtD
Thalidomide—Asthenia—Citalopram—alcohol dependence	7.79e-05	0.000451	CcSEcCtD
Thalidomide—Pruritus—Citalopram—alcohol dependence	7.68e-05	0.000445	CcSEcCtD
Thalidomide—Diarrhoea—Citalopram—alcohol dependence	7.43e-05	0.00043	CcSEcCtD
Thalidomide—CYP3A5—Biological oxidations—CYP2E1—alcohol dependence	7.36e-05	0.000909	CbGpPWpGaD
Thalidomide—CYP3A5—Metapathway biotransformation—CYP2E1—alcohol dependence	7.26e-05	0.000896	CbGpPWpGaD
Thalidomide—Dizziness—Citalopram—alcohol dependence	7.18e-05	0.000416	CcSEcCtD
Thalidomide—CYP2C19—Biological oxidations—ALDH2—alcohol dependence	7.12e-05	0.000879	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EP300—alcohol dependence	7.1e-05	0.000876	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor—EP300—alcohol dependence	7.1e-05	0.000876	CbGpPWpGaD
Thalidomide—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—alcohol dependence	7.08e-05	0.000874	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—GRIN2B—alcohol dependence	7.07e-05	0.000873	CbGpPWpGaD
Thalidomide—CYP1A1—Phase 1 - Functionalization of compounds—POMC—alcohol dependence	7.01e-05	0.000866	CbGpPWpGaD
Thalidomide—CYP1A2—Phase II conjugation—GGT1—alcohol dependence	6.96e-05	0.000859	CbGpPWpGaD
Thalidomide—CYP1A1—Biological oxidations—CYP2E1—alcohol dependence	6.95e-05	0.000859	CbGpPWpGaD
Thalidomide—Vomiting—Citalopram—alcohol dependence	6.9e-05	0.0004	CcSEcCtD
Thalidomide—CYP1A2—Phase 1 - Functionalization of compounds—MAOA—alcohol dependence	6.87e-05	0.000848	CbGpPWpGaD
Thalidomide—CYP1A1—Metapathway biotransformation—CYP2E1—alcohol dependence	6.86e-05	0.000847	CbGpPWpGaD
Thalidomide—Rash—Citalopram—alcohol dependence	6.84e-05	0.000397	CcSEcCtD
Thalidomide—Dermatitis—Citalopram—alcohol dependence	6.84e-05	0.000396	CcSEcCtD
Thalidomide—Headache—Citalopram—alcohol dependence	6.8e-05	0.000394	CcSEcCtD
Thalidomide—CYP2E1—Biological oxidations—GGT1—alcohol dependence	6.77e-05	0.000836	CbGpPWpGaD
Thalidomide—CYP3A5—Biological oxidations—GGT1—alcohol dependence	6.76e-05	0.000834	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Breast Cancer Pathway—EP300—alcohol dependence	6.56e-05	0.00081	CbGpPWpGaD
Thalidomide—CYP1A2—Biological oxidations—MAOB—alcohol dependence	6.52e-05	0.000805	CbGpPWpGaD
Thalidomide—CYP2C9—Biological oxidations—ALDH2—alcohol dependence	6.49e-05	0.000801	CbGpPWpGaD
Thalidomide—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—alcohol dependence	6.45e-05	0.000797	CbGpPWpGaD
Thalidomide—Nausea—Citalopram—alcohol dependence	6.45e-05	0.000374	CcSEcCtD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—EP300—alcohol dependence	6.39e-05	0.000789	CbGpPWpGaD
Thalidomide—CYP1A1—Biological oxidations—GGT1—alcohol dependence	6.38e-05	0.000788	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—OPRK1—alcohol dependence	6.09e-05	0.000752	CbGpPWpGaD
Thalidomide—CYP2E1—Biological oxidations—MAOA—alcohol dependence	6.07e-05	0.000749	CbGpPWpGaD
Thalidomide—CYP3A5—Biological oxidations—MAOA—alcohol dependence	6.05e-05	0.000748	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—OPRK1—alcohol dependence	5.78e-05	0.000713	CbGpPWpGaD
Thalidomide—CYP2C19—Phase 1 - Functionalization of compounds—POMC—alcohol dependence	5.74e-05	0.000708	CbGpPWpGaD
Thalidomide—CYP1A1—Biological oxidations—MAOA—alcohol dependence	5.72e-05	0.000706	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ADH6—alcohol dependence	5.7e-05	0.000704	CbGpPWpGaD
Thalidomide—CYP2C19—Biological oxidations—CYP2E1—alcohol dependence	5.69e-05	0.000703	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—WASF2—alcohol dependence	5.64e-05	0.000697	CbGpPWpGaD
Thalidomide—CYP2C19—Metapathway biotransformation—CYP2E1—alcohol dependence	5.61e-05	0.000693	CbGpPWpGaD
Thalidomide—CYP1A2—Biological oxidations—ALDH2—alcohol dependence	5.54e-05	0.000685	CbGpPWpGaD
Thalidomide—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—alcohol dependence	5.51e-05	0.000681	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—EP300—alcohol dependence	5.43e-05	0.000671	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—WASF1—alcohol dependence	5.41e-05	0.000668	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—GRIN2B—alcohol dependence	5.38e-05	0.000665	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—WASF2—alcohol dependence	5.35e-05	0.000661	CbGpPWpGaD
Thalidomide—PTGS1—Biological oxidations—POMC—alcohol dependence	5.29e-05	0.000653	CbGpPWpGaD
Thalidomide—CYP2C9—Phase 1 - Functionalization of compounds—POMC—alcohol dependence	5.23e-05	0.000646	CbGpPWpGaD
Thalidomide—CYP2C19—Biological oxidations—GGT1—alcohol dependence	5.22e-05	0.000645	CbGpPWpGaD
Thalidomide—CYP2C9—Biological oxidations—CYP2E1—alcohol dependence	5.19e-05	0.000641	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—WASF1—alcohol dependence	5.13e-05	0.000634	CbGpPWpGaD
Thalidomide—CYP2C9—Metapathway biotransformation—CYP2E1—alcohol dependence	5.12e-05	0.000632	CbGpPWpGaD
Thalidomide—PTGS2—C-MYB transcription factor network—EP300—alcohol dependence	4.94e-05	0.00061	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—EP300—alcohol dependence	4.87e-05	0.000601	CbGpPWpGaD
Thalidomide—CYP2C9—Biological oxidations—GGT1—alcohol dependence	4.76e-05	0.000588	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ADH1A—alcohol dependence	4.73e-05	0.000584	CbGpPWpGaD
Thalidomide—CYP2C19—Biological oxidations—MAOA—alcohol dependence	4.68e-05	0.000578	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ADH6—alcohol dependence	4.53e-05	0.000559	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—alcohol dependence	4.52e-05	0.000559	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—EP300—alcohol dependence	4.52e-05	0.000559	CbGpPWpGaD
Thalidomide—CYP1A2—Phase 1 - Functionalization of compounds—POMC—alcohol dependence	4.47e-05	0.000552	CbGpPWpGaD
Thalidomide—CYP1A2—Biological oxidations—CYP2E1—alcohol dependence	4.43e-05	0.000547	CbGpPWpGaD
Thalidomide—CYP1A2—Metapathway biotransformation—CYP2E1—alcohol dependence	4.37e-05	0.00054	CbGpPWpGaD
Thalidomide—CYP2C9—Biological oxidations—MAOA—alcohol dependence	4.27e-05	0.000527	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ADH6—alcohol dependence	4.26e-05	0.000526	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ADH6—alcohol dependence	4.25e-05	0.000525	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—EP300—alcohol dependence	4.19e-05	0.000518	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—EP300—alcohol dependence	4.14e-05	0.000511	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—OPRD1—alcohol dependence	4.09e-05	0.000505	CbGpPWpGaD
Thalidomide—CYP1A2—Biological oxidations—GGT1—alcohol dependence	4.07e-05	0.000503	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ADH6—alcohol dependence	4.02e-05	0.000496	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ADH4—alcohol dependence	4.02e-05	0.000496	CbGpPWpGaD
Thalidomide—CYP2E1—Biological oxidations—POMC—alcohol dependence	3.95e-05	0.000488	CbGpPWpGaD
Thalidomide—CYP3A5—Biological oxidations—POMC—alcohol dependence	3.94e-05	0.000487	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PDYN—alcohol dependence	3.92e-05	0.000485	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—OPRD1—alcohol dependence	3.88e-05	0.00048	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ADH1A—alcohol dependence	3.75e-05	0.000463	CbGpPWpGaD
Thalidomide—CYP1A1—Biological oxidations—POMC—alcohol dependence	3.72e-05	0.00046	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PDYN—alcohol dependence	3.72e-05	0.00046	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CRHR1—alcohol dependence	3.65e-05	0.00045	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—WASF2—alcohol dependence	3.65e-05	0.00045	CbGpPWpGaD
Thalidomide—CYP1A2—Biological oxidations—MAOA—alcohol dependence	3.65e-05	0.00045	CbGpPWpGaD
Thalidomide—CYP1A1—PPARA activates gene expression—EP300—alcohol dependence	3.53e-05	0.000436	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ADH1A—alcohol dependence	3.53e-05	0.000436	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ADH1A—alcohol dependence	3.52e-05	0.000435	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—WASF1—alcohol dependence	3.5e-05	0.000432	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—GGT1—alcohol dependence	3.48e-05	0.00043	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—WASF2—alcohol dependence	3.46e-05	0.000427	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CRHR1—alcohol dependence	3.46e-05	0.000427	CbGpPWpGaD
Thalidomide—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—alcohol dependence	3.46e-05	0.000427	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CHRM2—alcohol dependence	3.43e-05	0.000424	CbGpPWpGaD
Thalidomide—FGFR2—Disease—GOT2—alcohol dependence	3.43e-05	0.000423	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ADH7—alcohol dependence	3.42e-05	0.000422	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ADH1A—alcohol dependence	3.33e-05	0.000411	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—WASF1—alcohol dependence	3.32e-05	0.00041	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ADH6—alcohol dependence	3.29e-05	0.000406	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GGT2—alcohol dependence	3.28e-05	0.000405	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CHRM2—alcohol dependence	3.25e-05	0.000402	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ADH4—alcohol dependence	3.19e-05	0.000394	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—OPRM1—alcohol dependence	3.15e-05	0.000389	CbGpPWpGaD
Thalidomide—CYP2C19—Biological oxidations—POMC—alcohol dependence	3.05e-05	0.000376	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ADH4—alcohol dependence	3e-05	0.000371	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ADH6—alcohol dependence	3e-05	0.00037	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ADH4—alcohol dependence	3e-05	0.00037	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ADH1B—alcohol dependence	3e-05	0.00037	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—OPRM1—alcohol dependence	2.99e-05	0.000369	CbGpPWpGaD
Thalidomide—FGFR2—Disease—GOT1—alcohol dependence	2.96e-05	0.000365	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NPY—alcohol dependence	2.9e-05	0.000358	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ADH4—alcohol dependence	2.83e-05	0.00035	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HTR1B—alcohol dependence	2.8e-05	0.000345	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CRH—alcohol dependence	2.8e-05	0.000345	CbGpPWpGaD
Thalidomide—CYP2C9—Biological oxidations—POMC—alcohol dependence	2.78e-05	0.000343	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—GGT1—alcohol dependence	2.76e-05	0.000341	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NPY—alcohol dependence	2.75e-05	0.00034	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ADH1A—alcohol dependence	2.72e-05	0.000336	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ADH7—alcohol dependence	2.71e-05	0.000335	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HTR1B—alcohol dependence	2.65e-05	0.000328	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CRH—alcohol dependence	2.65e-05	0.000328	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GGT2—alcohol dependence	2.6e-05	0.000321	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ADH6—alcohol dependence	2.56e-05	0.000316	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—alcohol dependence	2.56e-05	0.000316	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ADH7—alcohol dependence	2.55e-05	0.000315	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ADH7—alcohol dependence	2.55e-05	0.000315	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—EP300—alcohol dependence	2.54e-05	0.000314	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ADH1A—alcohol dependence	2.48e-05	0.000307	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—MAOB—alcohol dependence	2.48e-05	0.000307	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—GGT1—alcohol dependence	2.45e-05	0.000303	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GGT2—alcohol dependence	2.45e-05	0.000302	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—DRD4—alcohol dependence	2.44e-05	0.000302	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GGT2—alcohol dependence	2.44e-05	0.000302	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ADH7—alcohol dependence	2.41e-05	0.000297	CbGpPWpGaD
Thalidomide—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—alcohol dependence	2.38e-05	0.000294	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ADH1B—alcohol dependence	2.38e-05	0.000294	CbGpPWpGaD
Thalidomide—CYP1A2—Biological oxidations—POMC—alcohol dependence	2.37e-05	0.000293	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CNR1—alcohol dependence	2.33e-05	0.000288	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—DRD4—alcohol dependence	2.32e-05	0.000286	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ADH4—alcohol dependence	2.32e-05	0.000286	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GGT2—alcohol dependence	2.31e-05	0.000285	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—DRD2—alcohol dependence	2.28e-05	0.000281	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HTR7—alcohol dependence	2.28e-05	0.000281	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—EP300—alcohol dependence	2.24e-05	0.000277	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ADH1B—alcohol dependence	2.24e-05	0.000276	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ADH1B—alcohol dependence	2.23e-05	0.000276	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CNR1—alcohol dependence	2.21e-05	0.000273	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—DRD2—alcohol dependence	2.16e-05	0.000267	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HTR7—alcohol dependence	2.16e-05	0.000267	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—EP300—alcohol dependence	2.13e-05	0.000263	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ADH1A—alcohol dependence	2.12e-05	0.000262	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ADH4—alcohol dependence	2.11e-05	0.000261	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ALDH2—alcohol dependence	2.11e-05	0.000261	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ADH1B—alcohol dependence	2.11e-05	0.000261	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—POMC—alcohol dependence	2.03e-05	0.000251	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—GGT1—alcohol dependence	2.01e-05	0.000248	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—MAOB—alcohol dependence	1.97e-05	0.000243	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ADH7—alcohol dependence	1.97e-05	0.000243	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—EP300—alcohol dependence	1.94e-05	0.000239	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—AVP—alcohol dependence	1.92e-05	0.000237	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GGT2—alcohol dependence	1.89e-05	0.000233	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—MAOB—alcohol dependence	1.86e-05	0.000229	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—MAOB—alcohol dependence	1.85e-05	0.000229	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—GGT1—alcohol dependence	1.83e-05	0.000226	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—AVP—alcohol dependence	1.82e-05	0.000225	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ADH4—alcohol dependence	1.81e-05	0.000223	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ADH7—alcohol dependence	1.8e-05	0.000222	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GOT2—alcohol dependence	1.79e-05	0.000222	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—MAOB—alcohol dependence	1.75e-05	0.000216	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ADH1B—alcohol dependence	1.73e-05	0.000213	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GGT2—alcohol dependence	1.72e-05	0.000213	CbGpPWpGaD
Thalidomide—PTGS2—Disease—GOT2—alcohol dependence	1.7e-05	0.00021	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CYP2E1—alcohol dependence	1.69e-05	0.000208	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ALDH2—alcohol dependence	1.68e-05	0.000207	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—POMC—alcohol dependence	1.61e-05	0.000199	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HTR2A—alcohol dependence	1.59e-05	0.000197	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ALDH2—alcohol dependence	1.58e-05	0.000195	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ADH1B—alcohol dependence	1.57e-05	0.000194	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ALDH2—alcohol dependence	1.57e-05	0.000194	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—GGT1—alcohol dependence	1.56e-05	0.000193	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GOT1—alcohol dependence	1.55e-05	0.000191	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GGT1—alcohol dependence	1.55e-05	0.000191	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ADH7—alcohol dependence	1.53e-05	0.00019	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HTR2A—alcohol dependence	1.51e-05	0.000187	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ALDH2—alcohol dependence	1.49e-05	0.000184	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GGT2—alcohol dependence	1.47e-05	0.000182	CbGpPWpGaD
Thalidomide—PTGS2—Disease—GOT1—alcohol dependence	1.47e-05	0.000181	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—MAOB—alcohol dependence	1.43e-05	0.000177	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—POMC—alcohol dependence	1.43e-05	0.000177	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GOT2—alcohol dependence	1.42e-05	0.000176	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—MAOA—alcohol dependence	1.39e-05	0.000171	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—EP300—alcohol dependence	1.35e-05	0.000166	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ADH1B—alcohol dependence	1.35e-05	0.000166	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GOT2—alcohol dependence	1.34e-05	0.000166	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CYP2E1—alcohol dependence	1.34e-05	0.000165	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GOT2—alcohol dependence	1.34e-05	0.000165	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—EP300—alcohol dependence	1.31e-05	0.000161	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—MAOB—alcohol dependence	1.31e-05	0.000161	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—POMC—alcohol dependence	1.27e-05	0.000157	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GOT2—alcohol dependence	1.26e-05	0.000156	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP2E1—alcohol dependence	1.26e-05	0.000155	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—EP300—alcohol dependence	1.24e-05	0.000153	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GOT1—alcohol dependence	1.23e-05	0.000152	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GGT1—alcohol dependence	1.23e-05	0.000152	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ALDH2—alcohol dependence	1.22e-05	0.00015	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—POMC—alcohol dependence	1.21e-05	0.000149	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CYP2E1—alcohol dependence	1.19e-05	0.000147	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—POMC—alcohol dependence	1.17e-05	0.000145	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GGT1—alcohol dependence	1.16e-05	0.000143	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GOT1—alcohol dependence	1.16e-05	0.000143	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GGT1—alcohol dependence	1.16e-05	0.000143	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GOT1—alcohol dependence	1.16e-05	0.000143	CbGpPWpGaD
Thalidomide—FGFR2—Disease—EP300—alcohol dependence	1.14e-05	0.000141	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MAOB—alcohol dependence	1.12e-05	0.000138	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ALDH2—alcohol dependence	1.11e-05	0.000137	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—MAOA—alcohol dependence	1.1e-05	0.000136	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GGT1—alcohol dependence	1.09e-05	0.000135	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GOT1—alcohol dependence	1.09e-05	0.000135	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—EP300—alcohol dependence	1.07e-05	0.000132	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—alcohol dependence	1.07e-05	0.000132	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—MAOA—alcohol dependence	1.04e-05	0.000128	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—MAOA—alcohol dependence	1.04e-05	0.000128	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GOT2—alcohol dependence	1.03e-05	0.000128	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—MAOA—alcohol dependence	9.78e-06	0.000121	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP2E1—alcohol dependence	9.73e-06	0.00012	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—EP300—alcohol dependence	9.49e-06	0.000117	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALDH2—alcohol dependence	9.48e-06	0.000117	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GOT2—alcohol dependence	9.44e-06	0.000117	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—POMC—alcohol dependence	9.12e-06	0.000113	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—POMC—alcohol dependence	9.04e-06	0.000112	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GOT1—alcohol dependence	8.93e-06	0.00011	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GGT1—alcohol dependence	8.93e-06	0.00011	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP2E1—alcohol dependence	8.87e-06	0.00011	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—EP300—alcohol dependence	8.45e-06	0.000104	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GGT1—alcohol dependence	8.14e-06	0.000101	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GOT1—alcohol dependence	8.14e-06	0.000101	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GOT2—alcohol dependence	8.06e-06	9.96e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—EP300—alcohol dependence	8.01e-06	9.9e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—MAOA—alcohol dependence	8e-06	9.89e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—alcohol dependence	7.76e-06	9.59e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP2E1—alcohol dependence	7.58e-06	9.36e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—MAOA—alcohol dependence	7.3e-06	9.01e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—POMC—alcohol dependence	7.18e-06	8.86e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—alcohol dependence	7.08e-06	8.74e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GOT1—alcohol dependence	6.96e-06	8.59e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GGT1—alcohol dependence	6.96e-06	8.59e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—POMC—alcohol dependence	6.75e-06	8.34e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—POMC—alcohol dependence	6.74e-06	8.32e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—POMC—alcohol dependence	6.37e-06	7.86e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MAOA—alcohol dependence	6.24e-06	7.7e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—EP300—alcohol dependence	6.05e-06	7.47e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—EP300—alcohol dependence	6e-06	7.4e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—EP300—alcohol dependence	5.68e-06	7.02e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—POMC—alcohol dependence	5.21e-06	6.44e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—EP300—alcohol dependence	4.76e-06	5.88e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—POMC—alcohol dependence	4.75e-06	5.87e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—EP300—alcohol dependence	4.48e-06	5.53e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—EP300—alcohol dependence	4.47e-06	5.52e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—EP300—alcohol dependence	4.22e-06	5.22e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—POMC—alcohol dependence	4.06e-06	5.01e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—EP300—alcohol dependence	3.46e-06	4.27e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—EP300—alcohol dependence	3.15e-06	3.89e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—EP300—alcohol dependence	2.69e-06	3.33e-05	CbGpPWpGaD
